by Aucentra Admin | Feb 25, 2022 | Aucentra News
24 February 2022 Adelaide, Australia- Aucentra Therapeutics is pleased to announce that it has received regulatory approval to progress to a Phase 1a/b clinical trial of Auceliciclib (AU3-14) in combination with Temozolomide for recurrent/refractory GBM patients....
by Aucentra Admin | Jan 25, 2022 | Aucentra News
Aucentra is thrilled to announce the appointment of John de Groot, MD, to our Scientific Advisory Board. Dr de Groot specializes in the treatment of patients with brain tumors, including glioblastomas and other gliomas. He is recognized for his expertise in...
by Aucentra Admin | Jan 25, 2022 | Aucentra News
Aucentra Therapeutics is delighted to announce the appointment of Professor Chris Pepper to our Scientific Advisory Board. Prof Chris Pepper is the Chair in Cancer Research at the Brighton and Sussex Medical School, UK. His research career has been extensive and...
by Aucentra Admin | Dec 14, 2021 | Aucentra News
Aucentra is excited to be awarded a seed-start grant of $700k by the South Australian government’s research and innovation fund. This funding will be used to test Aucentra’s leading drug candidate Auceliciclib. Auceliciclib, if successful in its clinical trials, will...
by Aucentra Admin | Nov 10, 2021 | Aucentra News
Pancreatic cancer has only a five-year survival rate of less than ten per cent, but Aucentra Therapeutics is hoping to reverse this with a new investigational drug call AU3-14 (Auceliciclib). AU3-14 is taken as an oral capsule and demonstrating safety and therapeutic...
Recent Comments